Safety, tolerability, and immunogenicity of Plasmodium falciparum sporozoite vaccine administered by direct venous inoculation to infants and young children: Findings from an age de-escalation, dose-escalation, double-blind, randomized controlled study in western Kenya
Clinical infectious diseases
Open Access Publication
Rights and Permissions
Laura C Steinhardt, Thomas L Richie, Reuben Yego, Dorcas Akach, Mary J Hamel, Julie R Gutman, Ryan E Wiegand, Elizabeth L Nzuu, Allan Dungani, Natasha Kc, Tooba Murshedkar, L W Preston Church, B Kim Lee Sim, Peter F Billingsley, Eric R James, Yonas Abebe, Simon Kariuki, Aaron M Samuels, Kephas Otieno, Tony Sang, S Patrick Kachur, David Styers, Kelly Schlessman, Ginnie Abarbanell, Stephen L Hoffman, Robert A Seder, Martina Oneko, Safety, Tolerability, and Immunogenicity of Plasmodium falciparum Sporozoite Vaccine Administered by Direct Venous Inoculation to Infants and Young Children: Findings From an Age De-escalation, Dose-Escalation, Double-blind, Randomized Controlled Study in Western Kenya, Clinical Infectious Diseases, Volume 71, Issue 4, 15 August 2020, Pages 1063–1071, https://doi.org/10.1093/cid/ciz925. Published by Oxford University Press for the Infectious Diseases Society of America 2019. This work is written by (a) US Government employee(s) and is in the public domain in the US. This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model).
Steinhardt, Laura C; Abarbanell, Ginnie; and et al., "Safety, tolerability, and immunogenicity of Plasmodium falciparum sporozoite vaccine administered by direct venous inoculation to infants and young children: Findings from an age de-escalation, dose-escalation, double-blind, randomized controlled study in western Kenya." Clinical infectious diseases. 71, 4. 1063 - 1071. (2020).
Supplemental material is available for this article at publisher site.